What does CUSIP 12648L601 represent in this 13F holders report?

CUSIP 12648L601 is the security identifier for CTIC - CTI BIOPHARMA CORP - COM used to aggregate holder disclosures.

How many institutions held CTIC - CTI BIOPHARMA CORP - COM in Q3 2017?

32 institutional investors reported CTIC - CTI BIOPHARMA CORP - COM for Q3 2017. Use the holders table for investor-level position and value details.

CTI BIOPHARMA CORP - COM (CTIC)

CUSIP: 12648L601

Q3 2017 13F Holders as of 30 Sep 2017

Type / Class: Equity / COM
Total 13F shares: 18,316,147
Share change: -95,247
Total reported value: $58,430,096
Price per share: $3.19
Number of holders: 32
Value change: -$406,478
Number of buys: 19
Number of sells: 8

Quarterly Holders Quick Answers

What is CUSIP 12648L601?
CUSIP 12648L601 identifies CTIC - CTI BIOPHARMA CORP - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Related Filing Research

Latest 13F filings for newly reported positions.
Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
Latest 10-Q/10-K reports for financial context tied to this issuer.
Recent insider transactions for executive and insider activity.
SEC investors directory and top value investors for manager drilldown.
Back to full security ownership history.

Institutional Holders of CTI BIOPHARMA CORP - COM (CTIC) as of Q3 2017

As of 30 Sep 2017, CTI BIOPHARMA CORP - COM (CTIC) was held by 32 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 18,316,147 shares. The largest 10 holders included BVF INC/IL, ORBIMED ADVISORS LLC, VANGUARD GROUP INC, Stonepine Capital Management, LLC, SPHERA FUNDS MANAGEMENT LTD., RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., DEUTSCHE BANK AG\, GEODE CAPITAL MANAGEMENT, LLC, and JPMORGAN CHASE & CO. This page lists 32 institutional shareholders reporting positions in this security for the Q3 2017 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.